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Abstract
Background: The pandemic 2009-H1N1 influenza virus circulated in the human population and caused thousands
deaths worldwide. Studies on pandemic influenza vaccines have shown that T cell recognition to conserved
epitopes and cross-reactive T cell responses are important when new strains emerge, especially in the absence of
antibody cross-reactivity. In this work, using HLA-B*4405 and DM1-TCR structure model, we systematically
generated high confidence conserved 2009-H1N1 T cell epitope candidates and investigated their potential cross-
reactivity against H5N1 avian flu virus.
Results: Molecular docking analysis of differential DM1-TCR recognition of the 2009-H1N1 epitope candidates
yielded a mosaic epitope (KEKMNTEFW) and potential H5N1 HA cross-reactive epitopes that could be applied as
multivalent peptide towards influenza A vaccine development. Structural models of TCR cross-recognition between
2009-H1N1 and 2004-H5N1 revealed steric and topological effects of TCR contact residue mutations on TCR
binding affinity.
Conclusions: The results are novel with regard to HA epitopes and useful for developing possible vaccination
strategies against the rapidly changing influenza viruses. Yet, the challenge of identifying epitope candidates that
result in heterologous T cell immunity under natural influenza infection conditions can only be overcome if more
structural data on the TCR repertoire become available.
Background
In 2009, the outbreak of a new swine-origin strain of
influenza A H1N1 caused widespread human infection
[1]. One of the most important surface proteins, hemag-
glutinin (HA) permits the virus to bind to cell membrane
and infect the cells. Since mutations enable the virus to
escape from either T cell or antibody recognition, current
flu vaccines were not effective against the emerging virus.
Sequence analyses showed that the HA sequence of the
pandemic 2009-H1N1 underwent an antigenic shift [2]
that altered its antigenicity in context of the seasonal flu
vaccine.
The antigenicity of HA 2009-H1N1 remained highly
conserved to pandemic 1918-H1N1 and partially con-
served to seasonal flu strains of the 1930s. Therefore, the
majority of infected individuals who were vaccinated with
the WHO recommended seasonal flu vaccine did not
produce neutralizing antibodies against the new influenza
strain. However, elderly and individuals born before 1950
were less affected than expected. The lower infection rate
of these age groups has been interpreted as the results of
cross-reactive T cells [3] and antibody [4] responses to
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the pandemic 1918-H1N1 and partially cross-reactive
T cell response to seasonal flu strains of the 1930s. A study
by Boon et al. [5] on CD8+ T cell recognition of heterosub-
typic H1N1 variants indicated that repeated infection with
heterologous viruses may increase cross-reactive Cytotoxic
T Lymphocytes (CTL) and thus confer protection against
newly emerging strains in absence of a cross-reactive anti-
body response. Further support for this concept comes
from a study of subjects who were vaccinated against sea-
sonal influenza and showed in vitro cross-reactive T cell
responses against HA of the pandemic 2009-H1N1 [6].
In growing recognition of the role of T cell responses to
H1N1, several groups conducted large-scale Human leu-
kocyte antigen (HLA) binding motif scanning analyses of
pandemic and seasonal strains to predict and identify con-
served peptides that elicit cross-reactive HLA class I and/
or class II restricted T cell responses [7-9]. While the affi-
nity-based approach allows a broad coverage of HLA
supertypes and epitope bindings [7,8], structural approach
gives better insight view onto T cell recognition of the
HLA-restricted T cell epitopes [10-12]. In our study, we
are interested in immunogenicity that depends on the
quality of T-cell receptor (TCR) interaction with the HLA/
peptide complexes rather than HLA-binding peptide affi-
nity only. We, therefore, combined affinity-based epitope
prediction with molecular docking to generate conserved
high confidence HA T cell epitope candidates of current
and past pandemic strains, and consequently analyzed
the potential TCR cross-recognition of 2009-H1N1 and
2004-H5N1.
According to Archbold et al. complex of DM1-TCR and
HLA-B*4405/peptide showed significant enhancement in
T cell-mediated responses among micropolymorphisms in
the HLA-B*44 family, and as such they are key factors in
controlling persistent viral infections [12]. Thus, to per-
form the experiments we used HLA-B*4405 and DM1-
TCR as models. Results of structural models of TCR
cross-recognition between 2009-H1N1 and 2004-H5N1
revealed steric and topological effects of TCR contact resi-
due mutations on TCR binding affinity. While these
results are novel with respect to HLA-B*4405-restricted
H1N1 HA epitopes and DM1-TCR, yet with limited avail-
able structural data upon the TCR repertoire, more inves-
tigations and experimental analyses are still recommended
for further broad perspective of their utility in vaccine
development against the emerging virus strains.
Results and discussion
Conserved HA T cell epitope candidates generated for
HLA-B*4405 and DM1-TCR
Examining various HA sequences among the pandemic
2009-H1N1, 1918-H1N1, and WHO recommended vac-
cine strains [Additional file 1], we predicted potential
9-mer T cell epitopes using the tool NetCTL v1.2 from
Immune Epitope Database (IEDB) (see Methods). Nine-
teen candidates, which scored greater than 0.75, are more
likely well presented by HLA-B44 family [Additional file
2]. We then docked these 19 epitopes to HLA-B*4405,
and subsequently the HLA-B*4405/epitope complex as
ligand to DM1-TCR. The 19 predicted epitope candidates
differ in their physico-chemical properties. Eight candi-
dates starting at positions 128, 188, 251, 131, 229, 400,
240, and 259 contain mostly hydrophobic and polar resi-
dues, whereas other 11 candidates (positions 50, 412, 446,
463, 493, 514, 421, 475, 482, 81, and 274) are composed of
predominantly hydrophilic residues [Additional file 3]
which result in higher HLA-B*4405 binding energies
(Table 1). As expected, all the 19 epitopes bound to the
helical antigen-presenting groove of the HLA-B*4405 [13].
Eleven epitopes (50, 128, 251, 412, 463, 493, 514, 131,
229, 400, and 259) bound in similar orientations to
HLA-B*4405 with Glu at position 2 and residues at the
C-terminus binding to the B and F pockets of the HLA-
B*4405, respectively [13-15]. Residues which occupy the
centre of the binding groove are solvent-exposed and
likely to bind to TCR [13,16]. In contrast, most residues of
epitopes at positions 188, 446, 421, 475, 482, and 240
interacted with the HLA-B*4405 peptide binding pockets.
In our model, the deeply embedded residues were not
exposed to the solvent. Therefore TCR recognition of
HLA-B*4405/epitope complexes is expected to be confor-
mationally restrained.
Table 1 Total binding energies of the 19 epitope
candidates (in descending HLA-B*4405 binding energy
ranks).
Position Sequence Docked to HLA-B*4405 Docked to DM1-TCR
Energy Rank Energy Rank
240 QEGRMNYYW -1,006 1 -541.7 17
188 KEVLVLWGI -921.8 2 -573.9 13
128 FERFEIFPK -869.9 3 -594.6 12
482 FEFYHKCDN -846.8 4 -743.9 2
259 FEATGNLVV -815.2 5 -608.9 10
400 IEKMNTQFT -775.8 6 -688.5 5
131 FEIFPKTSS -752.9 7 -560.5 14
251 VEPGDKITF -743.3 8 -599.1 11
229 PEIAIRPKV -687.7 9 -548.9 15
50 LEDKHNGKL -661.4 10 -552.1 16
274 MERNAGSGI -644 11 - -
514 REEIDGVKL -643.8 12 -666.3 7
81 PECESLSTA -633.3 13 - -
446 LENERTLDY -603.1 14 -621.1 9
412 KEFNHLEKR -599.5 15 -737.2 3
493 MESVKNGTY -543 16 -645 8
475 KEIGNGCFE -519.6 17 -715.4 4
463 YEKVRSQLK -475.3 18 -751.3 1
421 IENLNKKVD -464.6 19 -666.7 6
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DM1-TCR was docked to the HLA-B*4405/epitope com-
plexes to assess their binding conformation. In the models
with minimum binding energies, DM1-TCR Va and Vb
domains interacted with HLA-B*4405 a1 and a2 domain
residues and solvent exposed residues of the epitopes.
Epitope candidates 240 and 482 were embedded in the
binding groove of HLA-B*4405, and interacted with DM1-
TCR via Tyr7 and Tyr8 (epitope 240) and Lys6 (epitope
482) as shown in Table 2. These interactions appeared to
be mediated by a change of the TCR binding position to
HLA-B*4405 a1- and a2-domain residues, resulting in
contacts with polar and charged residues Asn70, Glu76,
and Gln155 of the HLA-B*4405. Hydrogen bond lengths
(in Å) and dihedrals around these H-bonds made by
DM1-TCR and HLA-B*4405 domains in cases of exposed
and embedded epitope types were calculated. In case of
epitope 259, residues at positions 4, 5, and 6 were exposed
while the TCR Va domain interacted with Asn
70 (2.1 Å)
and Glu76 (2.2 Å). In contrast, for the embedded-type epi-
tope 240, we observed binding of TCR Vb domain to
Asn70 and Glu76 at 2.5 Å H-bond lengths. Epitope candi-
dates 400 (exposed-type) and 482 (embedded-type) also
showed similar noticeable H-bond length changes.
Distances of the TCR to the residues Gln155 (HLA-a2)
decreased when the contacts with the HLA domains
shifted from the TCR Vb to TCR Va. Meanwhile, the dihe-
drals between residues that made the H-bonds also
showed decreasing trend when the TCR changed its bind-
ing positions to the HLA-B*4405 from Vb to Va domain
(e.g. from -133.7° to -54.1° in cases of epitope 240 and 259
respectively) [Additional file 4]. It could suggest that the
changes in H-bond lengths and dihedral angles indicate an
attempt of the TCR to adjust its binding access to the
HLA-B*4405/epitope complexes when the epitopes change
from exposed to embedded type.
Epitope candidates at positions 81 and 274 in 1918 and
WHO vaccine sequences [Additional file 2] yielded rather
low HLA-B*4405 binding scores (less than threshold
0.75) and could not be docked to DM1-TCR. Therefore
it is unlikely that the two candidate epitopes were anti-
genic to the 1918 and WHO strains. Mutations at posi-
tions 81 and/or 274 in HA sequences of the 2009 viral
strains increased the HLA-B*4405 binding scores above
the threshold, but did not facilitate TCR recognition in
our model.
Recognition of computationally inferred optimal epitope
KEKMNTEFW by HLA-B4405 and DM1-TCR
We computationally designed the mosaic epitope candi-
date KEKMNTEFW from five epitope sequences, which
were in the top 5 ranks of DM1-TCR binding energy
(Table 1). These epitopes are at positions 463, 482, 412,
475, and 400, whose corresponding residue positions
were favourably bound by the DM1-TCR model. We
selected the epitope IEKMNTQFT at position 400 as the
starting point because most of its residues made direct
contacts with DM1-TCR, i.e. -EKMNT—(Table 2). Also,
Archbold et al. [12] suggested that the second positioned
residue Glu (E2) be required for preferential binding to
HLA-B44. According to our top 5 DM1-TCR docking
results, 2 out of 5 epitopes (412 and 475) contain residue
Lys (K) at the first position, and Lysepitope475 directly
interacted with the DM1-TCR. Therefore, we used Lys
(K1) for the first position of the mosaic epitope. Similarly,
we chose Glu (E) for the 7th position since it was a TCR-
interacting residue of the epitope 412. Finally, we used
Table 2 2009-H1N1 HA epitope interacting residues with DM1-TCR and HLA-B*4405 complexes.
Position Epitope sequence HLA/epitope (solvent-exposed residues) TCR-HLA/epitope (interacting residues)
50 LEDKHNGKL Lys4 Lys4
128 FERFEIFPK Arg3, Glu5 Arg3
188 KEVLVLWGI - Lys1, Leu4, Leu6, Gly8
251 VEPGDKITF Asp5, Lys6 Asp5, Lys6
412 KEFNHLEKR Asn4, His5, Glu7 Glu2, Asn4, His5, Glu7
446 LENERTLDY - Leu1, Glu4, Asp8
463 YEKVRSQLK Arg5 Arg5, Lys9
493 MESVKNGTY Met1 Met1, Lys5
514 REEIDGVKL Lys8 Lys8
131 FEIFPKTSS Phe1 Phe1, Lys6
229 PEIAIRPKV Ala4, Ile5 Ile5
400 IEKMNTQFT Lys3, Met4 Glu2, Lys3, Met4, Asn5, Thr6
421 IENLNKKVD - Lys7, Asp9
475 KEIGNGCFE - Lys1, Glu2
482 FEFYHKCDN - Lys6
240 QEGRMNYYW - Asn6, Tyr7, Tyr8, Trp9
259 FEATGNLVV Thr4, Gly5, Asn6 Glu2, Thr4, Gly5
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bulky side-chains of F8 (Phe) and W9 (Trp) serving as
anchors for HLA-B*4405 binding. Thus, using Deep-
View [17], we substituted residues I1, Q7, and T9 with K,
E, and W respectively.
Docking of the mosaic epitope KEKMNTEFW to HLA-
B*4405 and DM1-TCR showed that it bound favourably to
both HLA-B*4405 (binding energy -849.5 kcal/mol; rank
4) and DM1-TCR (-684.4 kcal/mol; rank 6) with Asn5 and
Thr6 exposed to the solvent and directly interacting with
DM1-TCR. Although the HA peptide appears to be a
good candidate for inclusion in multivalent peptide vac-
cine against the H1N1 influenza A, its efficacy as a protec-
tive epitope on population level depends on the TCR
repertoire which could be only tested experimentally.
Cross-recognition of 2009-H1N1 and 2004-H5N1 HA T cell
epitope candidates
A study by Kreijtz et al. [18] showed that T cell responses
to seasonal H1N1 and H3N2 strains are largely cross-
reactive to avian H5N1. According to WHO Global Influ-
enza Program [19], H5 HA viral strain A/Vietnam/1194/
2004 of the avian flu outbreak in Vietnam was one of the
H5N1 prototype vaccine strains in 2005 and recom-
mended candidate of pre-pandemic H5N1 vaccine.
Therefore, we used HA protein of this strain as a model
to test if our 2009-H1N1 T cell epitope candidates would
be cross-reactive for 2004-H5N1.
NetCTL v1.2 was used to extract the 2004-H5N1 HLA-
B*4405 restricted T cell epitopes candidates from IEDB.
Of all candidates with predicted scores greater than 0.75,
seven were highly similar (greater than 78% similarity) to
the 2009-H1N1 T cell epitope candidates (Table 3) and
likely to be recognized by DM1-TCR.
Docking of the seven HLA-B*4405/2004-H5N1 epitope
complexes to DM1-TCR revealed that the DM1-TCR
predominantly interacted with the 2004-H5N1 epitopes
at conserved positions 50, 446, 493, and 475. DM1-TCR
binding energies of the 2004-H5N1 epitope candidates
were lower and thus more favourable than these of the
corresponding 2009-H1N1 epitope candidates (Table 3).
Most mutations that occurred between these two influ-
enza outbreaks did not appear to affect DM1-TCR recog-
nition of HLA-B*4405 presented epitope candidates.
However, we observed a significant decrease in TCR
binding energy of the epitope candidate 2004-H5N1 com-
plex at position 50 (Table 3). The mutation K4T changed
the structural conformation of the epitope’s exposed
region. The side chain of the mutated Thr4 pointed toward
the HLA-a2 domain and is embedded in the helical bind-
ing groove of the HLA-B*4405. It might therefore induce
the interactions of Lys8 and Leu9 at its C-terminal with
the DM1-TCR (Figure 1A). This could consequently
suggest a more favourable binding of DM1-TCR to the
HLA-B*4405/epitope50 in 2004-H5N1 than in 2009-
H1N1 viral strain.
In addition, we noticed that the binding affinity of DM1-
TCR to the 2004-H5N1 epitope candidates considerably
decreased when the TCR interactions occurred directly at
mutated residues of the epitope candidates at position 412
(H5N) and 421 (V8M and D9E). Substitution of a posi-
tively charged His with a smaller-sized neutral Asn
reduced the contact surface of the epitope candidate’s
exposed region (Figure 1B), resulting in a conformationally
constrained contact of DM1-TCR with 2004-H5N1 candi-
date epitope 412 and a higher binding energy (-640.8 kcal/
mol) compared to the 2009-H1N1 candidate epitope 412.
In a future pandemic we expect that apart from a few
mutated epitopes, heterologous immunity [20] mediated
by pre-existing cross-reactive T cell responses to seasonal
influenza virus will limit its severity and extent.
Conclusions
The HLA-B*4405 and DM1-TCR docking models showed
differential recognition of the 2009-H1N1 HA T cell epi-
tope candidates, reflecting the topological constraints of
the epitopes. This information was used to derive the syn-
thetic H1N1 epitope KEKMNTEFW with optimal recogni-
tion of both HLA-B*4405 and DM1-TCR models and to
identify likely cross-reactive 2004-H5N1 epitopes. While
the results are novel with regard to HLA-B*4405-restricted
H1N1 HA epitopes, their utility in vaccination strategies
against influenza viruses is limited by the fact that the T
cell responses to viruses depend on the TCR repertoire,
and in particular on the nature of TCR alpha chain and
their conformation as shown in a study by Zhong et al.
[21]. To simulate a T cell response to H1N1 epitopes on
population level as it is desirable for vaccine design, a
large number of crystal structure data on TCR Va and Vb
chains and their heterodimers would be necessary to com-
putationally assess epitope candidates for their potential to
induce a broad T cell response.
Methods
Obtaining HA candidate epitopes from pandemic (H1N1)
2009 sequences
Potential epitopes were predicted using T cell epitope pre-
diction tool (NetCTL v1.2) from IEDB [22,23]. NetCTL, a
neural network architecture-based tool, was used to pre-
dict T cell epitope candidates for HA proteins of current
H1N1 influenza A strains according to HLA-B44 super-
type. Weight parameters on C-terminal cleavage (0.15)
and transporter associated with antigen processing (TAP)
efficiency (0.05) were as default. There are 3 threshold
scores (0.75, 0.9, 1.0) that give both high sensitivity (0.8,
0.74, 0.7) and specificity (0.97, 0.98, 0.985) accordingly.
While the first 2 scores (0.75 and 0.9) obtained similar
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results of T cell epitopes, the score of 1.0 resulted only 7
epitopes (positions 240, 188, 128, 482, 400, 131, and 50)
shown in Table 1. Our docking results of HLA-B*4405
and the T cell epitope candidates showed that epitope can-
didates at positions 259, 251, and 229, which were located
in the top 10 HLA-binding energy rankings in Table 1,
would be missed if the 1.0 score was used.
Finally, as comparing to the score of 0.9, we selected
0.75 as the threshold for its better sensitivity (0.8) to
predict the potential T cell epitopes. Therefore candi-
dates with prediction scores greater than 0.75 were cho-
sen for further investigation. I-TASSER [24] was used to
obtain homology models of the selected T cell epitopes.
Molecular docking of predicted HLA-B*4405-binding
epitopes to T cell receptor DM1-TCR
The pipeline included docking the epitopes to HLA-
B*4405 [PDB:3DX8] and followed by docking of the HLA/
epitope complex as a ligand to DM1-TCR [PDB:3DXA].
The binding ability of the predicted epitopes was further
analyzed using ClusPro v.2 [25,26].
ClusPro v.2 is a web-based automated docking program
performing a multistage protocol: rigid PIPER docking,
filtering and clustering of docked conformations, and sta-
bilizing using Monte Carlo simulations [26]. During the
docking, HLA b-domain was masked but remained sur-
face accessible since it is not involved in interaction with
Table 3 Seven 2009-H1N1 T cell epitope candidates that could be cross-reactive with 2004-H5N1 T cell responses.
2009_H1N1
position
Strain Sequence MHC-bound predicted score Docked to HLA-B*4405 Docked to DM1-TCR
Energy Energy
50 2009-H1N1 LEDKHNGKL 1.0508 -661.4 -552.1
2004-H5N1 LEKTHNGKL 1.1478 -715.0 -682.2
412 2009-H1N1 KEFNHLEKR 0.9764 -599.5 -737.2
2004-H5N1 REFNNLEKR 0.9949 -638.9 -640.8
446 2009-H1N1 LENERTLDY 1.1929 -603.1 -621.1
2004-H5N1 MENERTLDF 1.5813 -563.5 -667.2
493 2009-H1N1 MESVKNGTY 1.73 -543.0 -645.0
2004-H5N1 MESVRNGTY 1.6645 -595.0 -667.5
421 2009-H1N1 IENLNKKVD 0.8563 -464.6 -666.0
2004-H5N1 IENLNKKME 0.7968 -466.1 -642.0
475 2009-H1N1 KEIGNGCFE 0.9892 -519.6 -715.4
2004-H5N1 KELGNGCFE 0.8258 -548.9 -733.8
482 2009-H1N1 FEFYHKCDN 1.1128 -846.8 -743.9
2004-H5N1 FEFYHKCDN 1.1129 -846.8 -743.9
*Different residues are underlined. The residues that interacted with DM1-TCR are highlighted in bold.
Two significant changes in TCR binding energy are marked in bold.
Figure 1 Conformational changes of DM1-TCR/HLA-B*4405/epitope complexes caused by epitope mutations. (A) Mutation K4T in the
exposed region of 2004-H5N1 epitope 50 induced interaction of the C-terminal Lys8 and Leu9 with DM1-TCR. (B) Reduced exposed DM1-TCR
(grey) contact area caused by mutation H5N of 2004-H5N1 epitope 412. Epitopes are shown in green (2004-H5N1) and magenta (2009-H1N1).
Residue side chains are presented as lines.
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the TCR [13]. The results were clustered according to
their binding energies. The binding energy score (hereby
called “binding energy”) is generated from an energy
function of PIPER docking program. This function is a
sum of potential terms of shape complementarity, elec-
trostatics, desolvation contributions, and Decoys as refer-
ence states (DARS) [25]. According to Kozakov et al., the
core idea of the knowledge-based potential DARS counts
on observed numbers of intermolecular interactions [25].
Therefore we filtered our docking results by selecting
docked complexes that belonged to the most populated
clusters of interacting complexes but with lowest binding
energy scores for our final results. We assumed that the
model with minimum binding energy was the optimal
conformation.
Then, we performed molecular dynamics (MD) simu-
lations using AMBER 10 force field ff99SB [27] to
improve the bound conformation of rigid docking. The
TCR-HLA/epitope docked complexes underwent a
3-stage MD simulation (minimization, heating, and
equilibration) using explicit solvent model under peri-
odic boundary condition. In the minimization process,
we applied a weak positional restraint using a force con-
stant of 500 kcal/molÅ2 on the whole complex during
the first 1,000 steps under restrained conditions, while
initially minimizing positions of solvent and sodium
ions. For the subsequent 2,500 steps of minimization,
we removed this restraint. The constant volume was set
during both the 2 stages of the minimization process. In
the heating stage of 20 ps, we restrained the complex
again, but with only 10 kcal/molÅ2 to avoid wild fluc-
tuations in the structure. We allowed the system to heat
up from 0 K to 300 K and applied the Langevin tem-
perature equilibration scheme to control the tempera-
ture. Then, a short equilibration stage (1ns) without the
restraints was performed in constant pressure of 1 atm
and at 300 K. We used SHAKE in both heating and
equilibration stages to constrain bonds that involves
hydrogen. As a result, complexes obtained from the MD
simulation above were considered final bound confor-
mations of the docked TCR-HLA/epitope complexes in
our study.
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